Crystal products of lamotrigine-citric acid for improvement of in vitro drug release in simulated gastric fluid

Bhabani Sankar Satapathy, Asuprita Patel, Rudra Narayan Sahoo, Subrata Mallick


Crystal engineering is an integral part of the drug development research. Crystal forms can modify the physicochemical properties of the parent drug molecule. The present work was aimed at the synthesis and characterization of crystalline product of lamotrigine (LT), a FDA approved anti-epileptic drug, with citric acid (CA) to improve its release in gastric region and oral absorption. The crystalline products of LT-CA were developed by solvent evaporation method using ethanol-water as the solvent system. Appearance of new charac­teristic peaks in the FTIR spectra for the crystal products indicated formation of new crystal state. In DSC thermogram, melting point of the experimental crystal products was different than that of the pure drug. Further, formation of new crystalline phase was confirmed from XRD data through the identification of new sharp peaks for the selected crystal products. A higher cumulative percen­tage of drug release was observed for the crystal products than the free drug within 60 min of drug release in simulated gastric fluid. However, in vivo studies are warranted for the future technology transfer of the product at industrial scale.


Anti-epileptic; onset of action; BCS class II; solvent evaporation method; lattice strain

Full Text:

PDF (993 kB)


A. K. El-Yafi, H. El-Zein, Asian J. Pharm. Sci. 10 (2015) 283 (

N. Blagden, M. De Matas, P. T. Cavan, Adv. Drug Deliv. Rev. 59 (2007) 617 (

R. N. Sahoo, A. De, V. Kataria, S. Mallick, Indian J. Pharm. Edu. Res. 53 (2019) s554 (

P. Jiaxin, W. Shuya, L. Wen, K. Dereje, Z. Ying, Z. Bing, Q. Dongli, G. Pan, L. Nan, L. Zhidong, Asian J. Pharm. Sci. 14 (2019) 154 (

S. Indumathi, D. Sameer, Pharmaceutics 10 (2018) 1 (

G. Péter, C. Pallagigábor, K. Orsolya, J. Piroska, S. Ambrus, Drug Des. Dev. Ther. 11 (2017) 2453 (

M. L. Cheney, N. Shan, E. R. Healey, M. Hanna, L. Wojtas, M. J. Zaworotko, V. Sava, S. Song, J. R. Sanchez-Ramos, Cryst. Growth Des. 10 (2010) 394-405 (

M. Lalic, A. Pilipovic,S. Golocorbin-Kon, K. Gebauer-Bukurov, K. Bozic, M. Mikov , J. Cvejic, Drugs R & D. 11 (2011) 53 (

C. Patil, S. Das, Afr. J. Pharm. Pharmacol. 5 (2009)76-82 (

P. Chappa, A. Maruthapillai, M. Tamilselvi, S. Devikala, J. A Selvi, Mater. Today: Proceedings. 14 (2019) 504 (

K. Nigam, A. Kaur, A. Tyagi, M. Nematullah, F. Khan, R. Gabrani, Drug Deliv. Transl. Res. 18 (2019) 1 (

K. Wen, J. Shao, X. Shen, L. Ping, L. A. Ping, Z. Juying, Z. Jin, Cryst. Growth Des. 10 (2019) 1 (

Z. Rahman, C. Agarabi, A. S. Zidan, S. R. Khan, M. A. Khan, AAPS PharmSciTech. 12 (2011) 693 (

A. Merdoud, M. Mouffok, A. Mesli, N. Chafi, M. Chaib, J. Serb. Chem. Soc. 85 (2020) 531 (

S. Mallick, S. K. Pradhan, M. Chandran, M. Acharya, T. Digdarsini, R. Mohapatra, Results Pharm. Sci. 1 (2011) 1 (

S. Mallick, P. K. Dey, S. Sannigrahi, A. Mitra, Acta Pol. Pharm. 61 (2004) 447 (

R. Mohapatra, S. Mallick, Asian J. Chem. 28 (2016) 1149 (

O. C. Larbi, H. Merine, Y. Ramli, F. B. Toumi, K. Guemra, A. Dehbi, J. Serb. Chem. Soc. 83 (2018) 1243 (

S. Patrycja, W. Marek, J. Therm. Anal. Calorim. 133 (2018) 785 (

T. S. Latha, M. C. Reddy, V. D. Prasad, S. V. Muthukonda, D. Lomada, Indian J. Pharmacol. 49 (2017) 458 (

H. Muhammad, S. Muhammad, R. Yousuf, F. Zafar, Plos One 13 (2018) 1 (

A. Pramanik, R. N. Sahoo, A. Nanda, R. Mohapatra, R. Singh, S. Mallick, Curr Eye Res. 43 (2018) 828-38. (


Copyright (c) 2020 Journal of the Serbian Chemical Society

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

5 Year Impact Factor 1.023
138 of 177 journals)